Cargando…

Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study

Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccarelli, Giancarlo, Borrazzo, Cristian, Pinacchio, Claudia, Santinelli, Letizia, Innocenti, Giuseppe Pietro, Cavallari, Eugenio Nelson, Celani, Luigi, Marazzato, Massimiliano, Alessandri, Francesco, Ruberto, Franco, Pugliese, Francesco, Venditti, Mario, Mastroianni, Claudio M., d'Ettorre, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829198/
https://www.ncbi.nlm.nih.gov/pubmed/33505983
http://dx.doi.org/10.3389/fnut.2020.613928
_version_ 1783641136421666816
author Ceccarelli, Giancarlo
Borrazzo, Cristian
Pinacchio, Claudia
Santinelli, Letizia
Innocenti, Giuseppe Pietro
Cavallari, Eugenio Nelson
Celani, Luigi
Marazzato, Massimiliano
Alessandri, Francesco
Ruberto, Franco
Pugliese, Francesco
Venditti, Mario
Mastroianni, Claudio M.
d'Ettorre, Gabriella
author_facet Ceccarelli, Giancarlo
Borrazzo, Cristian
Pinacchio, Claudia
Santinelli, Letizia
Innocenti, Giuseppe Pietro
Cavallari, Eugenio Nelson
Celani, Luigi
Marazzato, Massimiliano
Alessandri, Francesco
Ruberto, Franco
Pugliese, Francesco
Venditti, Mario
Mastroianni, Claudio M.
d'Ettorre, Gabriella
author_sort Ceccarelli, Giancarlo
collection PubMed
description Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy. Methods: This retrospective, observational cohort study included 200 adults with severe COVID-19 pneumonia. All patients received therapeutic regimens including low molecular weight heparin plus one or more between hydroxychloroquine, azithromycin, antivirals, and Tocilizumab. Oral bacteriotherapy was used as complementary treatment. Results: Out of the 200 patients, 112 received BAT without oral bacteriotherapy, and 88 BAT with oral bacteriotherapy. Crude mortality was 22%. Eleven percent died in the group of patients treated with BAT plus oral bacteriotherapy vs. 30% subjects in the group of patients managed only with BAT (p < 0.001). By multivariate analysis, the age >65 years, CRP >41.8 mg/L, Platelets <150.000 mmc, and cardiovascular events were associated with the increased risk of mortality. Oral bacteriotherapy was an independent variable associated with a reduced risk for death. Despite large prospective trials are needed, this study highlights a possible role for oral bacteriotherapy in the management of patients hospitalized for COVID-19 pneumonia.
format Online
Article
Text
id pubmed-7829198
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78291982021-01-26 Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study Ceccarelli, Giancarlo Borrazzo, Cristian Pinacchio, Claudia Santinelli, Letizia Innocenti, Giuseppe Pietro Cavallari, Eugenio Nelson Celani, Luigi Marazzato, Massimiliano Alessandri, Francesco Ruberto, Franco Pugliese, Francesco Venditti, Mario Mastroianni, Claudio M. d'Ettorre, Gabriella Front Nutr Nutrition Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy. Methods: This retrospective, observational cohort study included 200 adults with severe COVID-19 pneumonia. All patients received therapeutic regimens including low molecular weight heparin plus one or more between hydroxychloroquine, azithromycin, antivirals, and Tocilizumab. Oral bacteriotherapy was used as complementary treatment. Results: Out of the 200 patients, 112 received BAT without oral bacteriotherapy, and 88 BAT with oral bacteriotherapy. Crude mortality was 22%. Eleven percent died in the group of patients treated with BAT plus oral bacteriotherapy vs. 30% subjects in the group of patients managed only with BAT (p < 0.001). By multivariate analysis, the age >65 years, CRP >41.8 mg/L, Platelets <150.000 mmc, and cardiovascular events were associated with the increased risk of mortality. Oral bacteriotherapy was an independent variable associated with a reduced risk for death. Despite large prospective trials are needed, this study highlights a possible role for oral bacteriotherapy in the management of patients hospitalized for COVID-19 pneumonia. Frontiers Media S.A. 2021-01-11 /pmc/articles/PMC7829198/ /pubmed/33505983 http://dx.doi.org/10.3389/fnut.2020.613928 Text en Copyright © 2021 Ceccarelli, Borrazzo, Pinacchio, Santinelli, Innocenti, Cavallari, Celani, Marazzato, Alessandri, Ruberto, Pugliese, Venditti, Mastroianni and d'Ettorre. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Ceccarelli, Giancarlo
Borrazzo, Cristian
Pinacchio, Claudia
Santinelli, Letizia
Innocenti, Giuseppe Pietro
Cavallari, Eugenio Nelson
Celani, Luigi
Marazzato, Massimiliano
Alessandri, Francesco
Ruberto, Franco
Pugliese, Francesco
Venditti, Mario
Mastroianni, Claudio M.
d'Ettorre, Gabriella
Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title_full Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title_fullStr Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title_full_unstemmed Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title_short Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
title_sort oral bacteriotherapy in patients with covid-19: a retrospective cohort study
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829198/
https://www.ncbi.nlm.nih.gov/pubmed/33505983
http://dx.doi.org/10.3389/fnut.2020.613928
work_keys_str_mv AT ceccarelligiancarlo oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT borrazzocristian oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT pinacchioclaudia oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT santinelliletizia oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT innocentigiuseppepietro oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT cavallarieugenionelson oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT celaniluigi oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT marazzatomassimiliano oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT alessandrifrancesco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT rubertofranco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT pugliesefrancesco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT vendittimario oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT mastroianniclaudiom oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy
AT dettorregabriella oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy